RENE GONZALEZ to Dacarbazine
This is a "connection" page, showing publications RENE GONZALEZ has written about Dacarbazine.
Connection Strength
0.466
-
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91.
Score: 0.084
-
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
Score: 0.081
-
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
Score: 0.063
-
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
Score: 0.057
-
A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15; 94(2):470-6.
Score: 0.046
-
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
Score: 0.024
-
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.024
-
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec 20; 27(36):6207-12.
Score: 0.020
-
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
Score: 0.019
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
Score: 0.018
-
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
Score: 0.015
-
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005 Dec 10; 23(35):8992-9000.
Score: 0.015